Perspectives of stem cell therapy in Duchenne muscular dystrophy

Mirella Meregalli, Andrea Farini, Marzia Belicchi, Daniele Parolini, Letizia Cassinelli, Paola Razini, Clementina Sitzia, Yvan Torrente

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Muscular dystrophies are heritable and heterogeneous neuromuscular disorders characterized by the primary wasting of skeletal muscle, usually caused by mutations in the proteins forming the link between the cytoskeleton and the basal lamina. As a result of mutations in the dystrophin gene, Duchenne muscular dystrophy patients suffer from progressive muscle atrophy and an exhaustion of muscular regenerative capacity. No efficient therapies are available. The evidence that adult stem cells were capable of participating in the regeneration of more than their resident organ led to the development of potential stem cell treatments for degenerative disorder. In the present review, we describe the different types of myogenic stem cells and their possible use for the progression of cell therapy in Duchenne muscular dystrophy. Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy and unfortunately no effective therapy is available at present. As stem cells received much attention for their potential use in cell-based therapies for human diseases, herein we described multiple types of resident and circulating myogenic stem cells, their characterization and their possible use to treat muscular dystrophies.

Original languageEnglish
Pages (from-to)4251-4262
Number of pages12
JournalFEBS Journal
Volume280
Issue number17
DOIs
Publication statusPublished - Sep 2013

Fingerprint

Duchenne Muscular Dystrophy
Cell- and Tissue-Based Therapy
Stem cells
Muscular Dystrophies
Stem Cells
Muscle
Dystrophin
Mutation
Adult Stem Cells
Muscular Atrophy
Cytoskeleton
Basement Membrane
Regeneration
Skeletal Muscle
Therapeutics
Genes
Cells
Proteins

Keywords

  • Duchenne muscular dystrophy
  • stem cells
  • therapy

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Meregalli, M., Farini, A., Belicchi, M., Parolini, D., Cassinelli, L., Razini, P., ... Torrente, Y. (2013). Perspectives of stem cell therapy in Duchenne muscular dystrophy. FEBS Journal, 280(17), 4251-4262. https://doi.org/10.1111/febs.12083

Perspectives of stem cell therapy in Duchenne muscular dystrophy. / Meregalli, Mirella; Farini, Andrea; Belicchi, Marzia; Parolini, Daniele; Cassinelli, Letizia; Razini, Paola; Sitzia, Clementina; Torrente, Yvan.

In: FEBS Journal, Vol. 280, No. 17, 09.2013, p. 4251-4262.

Research output: Contribution to journalArticle

Meregalli, M, Farini, A, Belicchi, M, Parolini, D, Cassinelli, L, Razini, P, Sitzia, C & Torrente, Y 2013, 'Perspectives of stem cell therapy in Duchenne muscular dystrophy', FEBS Journal, vol. 280, no. 17, pp. 4251-4262. https://doi.org/10.1111/febs.12083
Meregalli M, Farini A, Belicchi M, Parolini D, Cassinelli L, Razini P et al. Perspectives of stem cell therapy in Duchenne muscular dystrophy. FEBS Journal. 2013 Sep;280(17):4251-4262. https://doi.org/10.1111/febs.12083
Meregalli, Mirella ; Farini, Andrea ; Belicchi, Marzia ; Parolini, Daniele ; Cassinelli, Letizia ; Razini, Paola ; Sitzia, Clementina ; Torrente, Yvan. / Perspectives of stem cell therapy in Duchenne muscular dystrophy. In: FEBS Journal. 2013 ; Vol. 280, No. 17. pp. 4251-4262.
@article{02e8b1c088544b11b02dcb083003b876,
title = "Perspectives of stem cell therapy in Duchenne muscular dystrophy",
abstract = "Muscular dystrophies are heritable and heterogeneous neuromuscular disorders characterized by the primary wasting of skeletal muscle, usually caused by mutations in the proteins forming the link between the cytoskeleton and the basal lamina. As a result of mutations in the dystrophin gene, Duchenne muscular dystrophy patients suffer from progressive muscle atrophy and an exhaustion of muscular regenerative capacity. No efficient therapies are available. The evidence that adult stem cells were capable of participating in the regeneration of more than their resident organ led to the development of potential stem cell treatments for degenerative disorder. In the present review, we describe the different types of myogenic stem cells and their possible use for the progression of cell therapy in Duchenne muscular dystrophy. Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy and unfortunately no effective therapy is available at present. As stem cells received much attention for their potential use in cell-based therapies for human diseases, herein we described multiple types of resident and circulating myogenic stem cells, their characterization and their possible use to treat muscular dystrophies.",
keywords = "Duchenne muscular dystrophy, stem cells, therapy",
author = "Mirella Meregalli and Andrea Farini and Marzia Belicchi and Daniele Parolini and Letizia Cassinelli and Paola Razini and Clementina Sitzia and Yvan Torrente",
year = "2013",
month = "9",
doi = "10.1111/febs.12083",
language = "English",
volume = "280",
pages = "4251--4262",
journal = "FEBS Journal",
issn = "1742-464X",
publisher = "Wiley-Blackwell",
number = "17",

}

TY - JOUR

T1 - Perspectives of stem cell therapy in Duchenne muscular dystrophy

AU - Meregalli, Mirella

AU - Farini, Andrea

AU - Belicchi, Marzia

AU - Parolini, Daniele

AU - Cassinelli, Letizia

AU - Razini, Paola

AU - Sitzia, Clementina

AU - Torrente, Yvan

PY - 2013/9

Y1 - 2013/9

N2 - Muscular dystrophies are heritable and heterogeneous neuromuscular disorders characterized by the primary wasting of skeletal muscle, usually caused by mutations in the proteins forming the link between the cytoskeleton and the basal lamina. As a result of mutations in the dystrophin gene, Duchenne muscular dystrophy patients suffer from progressive muscle atrophy and an exhaustion of muscular regenerative capacity. No efficient therapies are available. The evidence that adult stem cells were capable of participating in the regeneration of more than their resident organ led to the development of potential stem cell treatments for degenerative disorder. In the present review, we describe the different types of myogenic stem cells and their possible use for the progression of cell therapy in Duchenne muscular dystrophy. Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy and unfortunately no effective therapy is available at present. As stem cells received much attention for their potential use in cell-based therapies for human diseases, herein we described multiple types of resident and circulating myogenic stem cells, their characterization and their possible use to treat muscular dystrophies.

AB - Muscular dystrophies are heritable and heterogeneous neuromuscular disorders characterized by the primary wasting of skeletal muscle, usually caused by mutations in the proteins forming the link between the cytoskeleton and the basal lamina. As a result of mutations in the dystrophin gene, Duchenne muscular dystrophy patients suffer from progressive muscle atrophy and an exhaustion of muscular regenerative capacity. No efficient therapies are available. The evidence that adult stem cells were capable of participating in the regeneration of more than their resident organ led to the development of potential stem cell treatments for degenerative disorder. In the present review, we describe the different types of myogenic stem cells and their possible use for the progression of cell therapy in Duchenne muscular dystrophy. Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy and unfortunately no effective therapy is available at present. As stem cells received much attention for their potential use in cell-based therapies for human diseases, herein we described multiple types of resident and circulating myogenic stem cells, their characterization and their possible use to treat muscular dystrophies.

KW - Duchenne muscular dystrophy

KW - stem cells

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=84882725695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882725695&partnerID=8YFLogxK

U2 - 10.1111/febs.12083

DO - 10.1111/febs.12083

M3 - Article

C2 - 23206279

AN - SCOPUS:84882725695

VL - 280

SP - 4251

EP - 4262

JO - FEBS Journal

JF - FEBS Journal

SN - 1742-464X

IS - 17

ER -